Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > October 28, 2022
Daily News
October 28, 2022
- Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
October 28, 2022
- Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
- Cancer-Savvy New CMO Eager to Extend Astellas’ Oncology Portfolio, Bag Speedy Approval
October 28, 2022
- Less than Half of Japan Prefectures Offer SMA Test under Newborn Screening Program: Survey
October 28, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…